Strong sales and profitability growth continued in Q2 2026, supported by a successful IPO and the acquisition of a US manufacturing facility. Robust demand across all end markets, especially telecom and life sciences, drove a 27.3% year-over-year sales increase and a 34.0% EBIT margin.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.